Non-Small Cell Lung Cancer

ALK+ NSCLC
Dr. Girard Discusses Results From PALOMA-2
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
Advertisement

Expert Interviews

Advertisement
Section Editor

Advertisement
Latest News

April 14, 2025